JDRF Names Dick Allen as Chairman of the Board
–Frank Ingrassia to retire as chairman of the board–
Contact: Joana Casas, 212-479-7560; email@example.com
New York, NY, April 30, 2012-JDRF, the leading global organization focused on type 1 diabetes (T1D) research, announced today that Dick Allen has been named Chairman of the Board for the organization, commencing July 1, 2012.
Allen has been involved with JDRF for more than 10 years on both the local and international levels. He has served on the JDRF International Board of Directors for the past four years, and currently chairs the Board’s Research Committee. He has served in a variety of Board positions, including Chair of the Audit and Research Development Committees, as well as a member of the Executive Committee.
Allen will replace Frank Ingrassia as JDRF’s Chairman. Ingrassia, President and Chief Executive Officer of Clever Devices, Ltd., will complete his two-year term as JDRF’s Chairman of the Board at the end of the organization’s fiscal year in June.
“My time as Chairman of the Board at JDRF has been an important part of my life, as I believe wholeheartedly in the organization, how far we have come, and the forward direction in which we are headed on behalf of people with type 1,” Ingrassia said. “I have the utmost confidence in Dick as he takes over the role of chairman, and I look forward to his continued successes with JDRF.”
“I have been committed to JDRF for a long time, and am honored and excited about this next stage of my involvement with an organization that I’m truly proud to be a part of,” Allen said. “Frank has been an outstanding Chairman, and while I have big shoes to fill, I also know that I’m stepping into the position on well-nourished soil.”
Allen has had a 40-year career in the healthcare industry, as both an operating executive and a seed capital investor and board member. He began his career at Baxter Healthcare, holding domestic and international management positions in finance and operations. After leaving Baxter, Allen co-founded Caremark, a venture capital-backed pioneer of intravenous therapies delivered in the home. He led the company’s finance and operations functions and played a key role in guiding its rapid growth and initial public offering. Since Caremark’s sale to Baxter in 1987, Allen has been an angel investor, providing seed capital for companies in the medical device arena, healthcare services, and healthcare IT markets. In this capacity, he has been a founder, board member, or early-stage investor in more than 30 companies. He cofounded Pyxis Corporation, the market leader in medication storage and dispensing devices for hospitals, and served on the executive committee of the board until its sale to Cardinal Health.
In addition to serving on the board of JDRF, Allen provides strategic oversight for the Mary and Dick Allen Diabetes Center at Hoag Hospital, and serves as chairman of the board of Tandem Diabetes Care. He is a past recipient of the Director of the Year award from the Orange County Forum for Corporate Directors, and a past chairman of the board of Hoag Memorial Hospital Presbyterian, the Orange County Community Foundation, and the Orange County Business Council. He served for 13 years on the faculty of the Stanford University Graduate School of Business as a lecturer in the field of strategic management.
Allen received a bachelor of arts (cum laude) from Yale University and a master of business administration from Stanford University Graduate School of Business. He was born and raised in Sioux City, IA, and has been married to his wife, Mary, for 46 years. They live in Newport Beach, California, and have two grown children and four grandchildren, one of whom has had T1D for more than 11 years.
In T1D, a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. People with T1D need to test their blood sugar and give themselves insulin (with injections or an insulin pump) multiple times every day, and carefully balance insulin doses with eating and daily activities throughout the day and night. However, insulin is not a cure for diabetes, and even with that intensive care, a significant portion of the day is still spent with either high or low blood sugar, placing people with T1D at risk for devastating complications such as heart attack, stroke, blindness, and amputation.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.
Since its founding in 1970, JDRF has awarded more than $1.7 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. More than 80 percent of JDRF’s expenditures directly support research and research-related education.